- LOGIN
- MemberShip
- 2026-05-14 01:01:05
- Policy
- The flu-coronavirus outbreak has been predicted
- by Kim, Jung-Ju Sep 15, 2022 05:55am
- Amid the prevailing pessimistic outlook that flu and COVID-19 will be all the rage at the same time this fall, quarantine authorities stressed that flu and COVID-19 vaccines should be vaccinated respectively. This is due to similar symptoms such as headaches and fever, which can be mistaken, and people are confused by rumors that "if getting the flu vaccine, pts don't have to get the COVID-19 vaccine." Jung Ki-seok, head of the COVID-19 Special Response Team at the Central Disaster and Safety Countermeasures Headquarters, explained this in a Q&A session at a regular COVID-19 briefing this morning (14th). According to Jeong, the flu and COVID-19 are not often distinguishable from symptoms, but the expected flu is not much different from the influenza A types H1N1 and H3N2 that they have experienced before, so the symptoms are not expected to be significantly different. "The flu has a very typical symptom that only the flu has," Jeong said. "It starts with a sudden fever, aching body, and a headache, and it is effective to take medicine within 48 hours, when the virus is relatively less proliferation," he explained. "Not all flu symptoms follow typical symptoms," Jeong said. COVID-19 Some patients may suddenly have a fever and get sick, but doctors may know a lot from experience because the symptoms of the typical flu and the typical COVID-19 are very different. However, in order to ensure accuracy and not to rely on experience, the test must be performed," he stressed. Jeong dismissed the false information such as "the COVID-19 vaccine helps prevent the flu," as "a groundless rumor." "Children should receive both vaccines at the same time as they do every season," he said. "On the day they visit the hospital, they can get both vaccines to arms at the same time." Jeong then recommended simultaneous vaccination, saying, "The Korea Centers for Disease Control and Prevention will soon announce the national vaccination project, and if the second flu vaccine comes out in early October, it can be received along with the COVID-19 vaccine."
- Company
- The NHIS signed a MOU with Viatris to manage chronic dz
- by Eo, Yun-Ho Sep 15, 2022 05:55am
- Viatris is working with the NHIS to improve the chronic disease management environment. The NIHS and Viatris signed a MOU at the headquarters of the Wonju Industrial Complex in Gangwon-do on the 1st to utilize educational materials for patients with chronic medical care. Through this business agreement, the two institutions said they will contribute to efficient disease management by diversifying the contents to be used for patient education and counseling in the pilot project for chronic disease management in primary care. Viatris will establish mutual cooperation to improve the quality of patient education materials by providing chronic disease education contents for public interest purposes and proposing the use and improvement of educational contents provided by Viatris. The primary medical chronic disease management pilot project is a project to provide continuous health care services by conducting a comprehensive evaluation of hypertension and diabetes patients at local clinics and establishing individual management plans from January 2019. Viatris, which signed an agreement with the corporation, is a Korean subsidiary of Viatris, a global healthcare company launched in November 2020 by Upjohn, which was Pfizer's business division, combined with Mylan. Park Ji-young, head of NHIS' chronic disease management office, explained, "We expect that doctors and patients' educational satisfaction will increase by utilizing high-quality educational materials provided by Viatris in clinics participating in the project." Kwon Yong-cheol, executive director of the Viatris Department of Medicine, said, "We are happy to contribute to the primary medical chronic disease management project. Viatris will continue to strive to fulfill its social responsibilities as a global healthcare company to improve treatment access and provide information for patients and medical staff based on experience accumulated in chronic diseases such as high blood pressure, diabetes, and dyslipidemia, he said.
- Company
- Complicated patent extension period than foreign countries
- by Kim, Jin-Gu Sep 14, 2022 05:50am
- The current system is advantageous for multinational companies, and many domestic companies welcome reorganization. The system for extending the duration of drug patents is expected to be reorganized. The Korean Intellectual Property Office established a related TF and prepared an improvement plan, and recently inquired about opinions in the pharmaceutical bio industry. The direction of improvement of the system, which has sharp interests between the original and generic companies, is largely in international harmony with the United States and Europe. ◆Xeljanz patent period, 27 years in Korea, 25 years in the U.S. and Europe...From institutional differences The Korean Intellectual Property Office has come up with a total of four improvement plans, and as one of them, it is known that it is considering allowing it to extend only one of the several patents registered in one drug, such as the U.S. and Europe. According to the pharmaceutical bio industry on the 14th, Pfizer's rheumatoid arthritis treatment Xeljanz has a patent duration of 25 years in the United States. This is the result of an extension of five years, which was delayed by clinical trials or permission and examination by regulatory agencies, for 20 years of the typical patent period. In the case of Europe, a 25-year patent period is guaranteed. Xeljanz has a patent duration of 27 years in Korea. This is because the basic patent period is 20 years, but the extended patent duration is different. The reason why the extended patent duration of the U.S., Europe, and Korea is different despite the same drug and the same patent is due to differences in institutions between countries. The original company registers as many patents as possible when it develops a single drug. About 10 patents are also attached to one drug, including material patents, usage patents, usage and capacity patents, formulation patents, and crystalline patents. This is because the more patents there are, the more advantageous it is to defend the challenges of generic companies. In the United States and Europe, only one of the several patents registered in one drug item is selected and extended. In fact, Pfizer applied for an extension of the duration (up to five years) for two material patents and one legal patent in Korea, respectively. In the process of recognizing the extension of the duration of the three patents, overlapping occurred between each period. As a result, the patent period for Xeljanz in Korea was set to be about two years (732 days) longer than that of the United States and Europe. ◆Each of several patents can be extended…Original company patent period is 1~2 years longer Each company is very active in extending the duration of patent rights in Korea because the longer the patent period is, the more advantageous it is to the original company. A total of 24 new drugs were newly licensed in Korea last year. As in the case of Xeljanz, two to three patents were registered per item, and the entire patent period was extended by applying for an extension of the duration of each patent. The problem is that while registration is easy in the case of the duration of the drug patent, it is very difficult to overcome the generic. According to the Korean Intellectual Property Office, from 1999 to last year, when the patent extension system was implemented, the number of applications for the extension of the patent period by original companies totaled 750. Among them, a total of 612 cases were registered, 65 were rejected, and 22 were returned or withdrawn. The remaining 48 cases are under review as of the end of last year. It means that if the original company applies for the extension of the patent period, 9 out of 10 cases will succeed. The results of generic to the extended patent duration are pessimistic. There have been challenges over the duration of patents extended from 2015 to last year, but they have not been completely overcome once. ◆ Domestic pharmaceutical company 'yes' vs multinational pharmaceutical company 'no'…Delivering Opinions to the Korean Intellectual Property Office Multinational pharmaceutical companies are opposed to the reorganization plan, given that the current system is favorable to the original company. In fact, it is known that the KRPIA conveyed its opposition to the Korean Intellectual Property Office. A local pharmaceutical company official said, is "patent an extended duration that it is impossible to overcome the Patent and Trademark Office in the direction is welcome and reform the system." and "A release of significant impact on NHS finances in the process of the delay." Another pharmaceutical industry official said, "The current patent extension system is quite similar to Japan's system." "As the global pharmaceutical bio-industry environment has changed, it seems meaningful to reorganize Korea's system in the U.S. and European ways," he said.
- Company
- Novartis Korea to close down Respiratory BU next month
- by Sep 14, 2022 05:50am
- Novartis Korea is expected to close down its Respiratory Business Unit and dispose of related products from October this year. According to industry sources on the 14th, Novartis Korea’s Respiratory Business Unit will be officially closed down next month as part of the company’s large-scale reorganization in progress at the global level. Currently, Novartis Korea is operated in two business units - Pharmaceuticals BU and Oncology BU. The Pharmaceuticals BU consists of Cardiovascular & Metabolic Diseases; Autoimmunity, Transplantation & Inflammatory Diseases; Skin Diseases. The global reorganization is being made to first integrate the Pharmaceuticals and Oncology Business Units and then divide them into an Innovative Medicines (IM) Division and an off-patent drug division. Specifically, as of October this year, Novartis Korea will be reorganized into 5 Business Units, ▲Hematology, ▲Solid Tumor, ▲CV & GTX, ▲Immunology, and ▲ In-Market & Business Innovation. The unit that had been in charge of respiratory diseases has been removed in the process. Novartis’s respiratory pipeline consists of ‘Enerzair (indacaterol/glycopyrronium/mometasone),’ a three-drug combination drug for asthma, and ‘Atectura (indacaterol acetate/mometasone),’ a once-daily fixed-dose combination drug. Both drugs are fairly new in the market, being approved in December 2020 and granted reimbursement in September last year. However, sales of the two drugs have been low, making around KRW 800 million in 1H this year. The company is speculated to have made this decision after judging that the growth potential of its respiratory treatments is low. Xolair, Novartis Korea’s highest-grossing asthma treatment, was allocated to the Immunology BU due to its mechanism of action and excluded from the restructuring process. When a dedicated unit is shut down, products in its care may be transferred outside. However, due to the small sales volume of the relevant products, their effect on the company's aggregate sales is expected to be negligible even with such a transfer. Employees in the Respiratory BU will also be reassigned. According to a Novartis Korea employee, the Respiratory Unit has around 10 people, including those in charge of marketing and sales. With the shutdown of the Respiratory BU, about 30% of them are known to have applied for voluntary retirement (ERP) that is being offered by the company. Novartis Korea said, “We are in the process of reorganizing our business units to focus on our core therapeutic areas in line with the strategic direction taken by our headquarters. Employees in our Respiratory BU that apply for voluntary retirement will go through relevant procedures, and those who do not will be reassigned to other departments according to their wishes and business needs.”
- Company
- Tylenol-focused sales for COVID-19-related use dispersed
- by Kim, Jin-Gu Sep 14, 2022 05:50am
- The stock shortage of major over-the-counter drugs used to relieve symptoms of COVID-19, such as general cold medicines and antipyretic analgesics, has been prolonged due to the resurgence of COVID-19. In this prolonged shortage, the demand that had been concentrated on Tylenol is being dispersed to other drugs. Tylenol was the only major household medicine for COVID-19 to see reduced sales in 1H this year. The other major household medicines for COVID-19 have all enjoyed an increase in sales. In particular, sales of Panpyrin, Coldaewon, Brufen, Champ, etc. have shown marked growth. ◆1H sales of Tylenol series record KRW 38.5 billion…drop 15% in one year According to the market research institution IQVIA on the 9th, the combined sales of the Tylenol series in 1H this year were KRW 38.5 billion. This is a 15% drop from the KRW 45.1 billion it had made in 1H last year. In its product line, sales of Tylenol tab fell 16% from KRW 33.6 billion to KRW 28.1 billion, and Tylenol 8 Hour ER by 33% from KRW 10 billion to 6.7 billion. Sales of Women’s Tylenol had also fallen slightly from KRW 500 million to 400 million. However, sales of Tylenol Cold S had increased by over 3 times from KRW 1 billion to 3.3 billion. Sales of Tylenol had steadily increased since the outbreak of the COVID-19 crisis. Its sales, which had been in the KRW 15.5 billion range in 1H 2020, rose to KRW 20.3 billion in 2020, then to KRW 45.1 billion in 2021, a near threefold increase in two years. With the COVID-19 vaccinations that started in earnest in 1H last year, the number of people who wished to stock up on Tylenol to alleviate side effects of vaccinations such as fever and muscle pain had surged, resulting in an extreme shortage of the product. However, its growth seems to have slowed this year. This slower sales growth is attributed to the unstable supply of Tylenol and the consumers’ stronger tendency to purchase other medicines containing the same ingredient this year. ◆Sales of Coldaewon·Brufen rise threefold in one year …due to surge in demand and expanded production line Other major general cold medicine and antipyretic analgesic brands other than the Tylenol series enjoyed a rise in sales. In particular, Panpyrin, Coldaewon, Brufen, and Champ had shown marked growth. In the case of Dong-A Pharmaceutical’s general cold medicine Panpyrin series, its sales, which had been KRW 13.4 billion in 1H last year, had increased 62% to KRW 21.8 billion in one year. Sales of Dong-A’s antipyretic analgesic Champ had also increased 168% from KRW 1.5 billion to KRW 4.1 billion in the same period. Daewon Pharmaceutical’s general cold medicine Coldaewon series had made 3.3 times more sales from KRW 2.6 billion in 1H last year to KRW 8.6 billion this year. Sales of Samil Pharmaceutical’s Brufen rose nearly 3 times in a year from KRW 1.2 billion in 1H last year to KRW 3.7 billion this year. Such a rise in sales is interpreted to be the result of those pharmaceutical companies’ active engagement in expanding their production performance in preparation for the increase in demand. Dong-A Pharmaceutical, Daewon Pharmaceutical, and Samil Pharmaceutical, among other companies, had actively increased their production capacity by expanding production facilities and increasing factory production utilization rates in response to the surge in demand for cold medicines and antipyretic analgesics in the aftermath of the resurgence of COVID-19 in February this year. Samil Pharmaceutical greatly expanded its ibuprofen production line this year. The production capacity of its ibuprofen syrup increased 2.5 times from 50,000 liters in 1H last year to 170,000 liters in 1H this year, and the production capacity of Brufen tab increased around 1.5 times from 15.37 million to 22.5 million during the same period. Dong-A Pharmaceutical’s utilization rate of the Panpyrin production line had also increased from 78% to 126% in 1H this year, and Daewon Pharmaceutical had also focused on the manufacture of COVID-19-related medicines including Coldaewon. ◆Sales of Korean Drug’s 'Haben'·Chong Kun Dang 'Modcol' rise over fivefold In addition, sales of Korean Drug’s 'Haben' and Chong Kun Dang’s 'Modcol' had also risen over fivefold in one year, benefiting from the shortage of major household medicines for COVID-19. Celltrion Pharm’s general cold medicine Whituben, Sama Pharm’s antipyretic analgesics Cetophen, and Hanmi Pharmaceutical’s Maxibupen had also increased by over twofold in one year. Ahngook Pharm’s Anyfen, GSK Consumer Healthcare’s Theraflu, Kolon Pharma’s Tramol, KyungDong Pharm’s Gnal-N, Bukwang Pharm’s Tacenol, GC Cross’s Taxen, Daewoong Pharmaceutical’s eZn has also increased by over 50%. Samjin Pharmaceutical’s Geworin saw a relatively small increase in sales. Geworin’s sales, which stood at KRW 7.2 billion last year, increased only 5% to record KRW 7.6 billion in 1H this year.
- Policy
- Lowest price falls to PVA
- by Lee, Tak-Sun Sep 14, 2022 05:50am
- Despite the increase from 1.5 billion won to 2 billion won based on claims, the industry "needs small and medium-sized pharmaceutical remedies." Some products fell to the lowest price under PVA this year. Most of the products of small and medium-sized pharmaceutical companies lost money. According to industries on the 12th, some products such as Dongkoo's Glyforce fell to the lowest price in the same formulation due to this PVA. Glyforce fell 7.7% from 482 won to 445 won under the PVA. As a result, it has become the lowest price among 51 capsules of Choline alfoscerate 0.4g, a brain function improvement. Richwood Trading Company's single-use Hyalon Eye Drops also saw two products fall to their lowest prices. Hyalon Eye Drops (single use 0.35 mg/0.35 mL) fell 9.6% from 198 won to 179 won. Hyalon Eye Drops (0.45mg/0.45mL for a single use), which has been equally reduced, is also the lowest price among 26 identical products. Arlico's hyperlipidemia drug Pitavastatin 2mg also became the lowest-priced product. This product fell 9.6% from 561 won to 507 won. The lowest price due to PVA cuts is mainly from small and medium-sized pharmaceutical companies. The NHIS raised the standard for product claims from 1.5 billion won to 2 billion won while improving the exclusion target of PVA. The move was aimed at relieving small and medium-sized pharmaceutical products with low sales. However, there are still opinions that want to improve as a number of small and medium-sized products are included in the PVA cut. The NHIS is also conducting research services to improve PVA by the end of the year.
- Company
- Novartis' application for voluntary retirement is closed
- by Sep 14, 2022 05:50am
- The application for ERP, which is underway by Novartis Korea, has ended. Attention is focusing on whether the relatively quiet voluntary retirement will be completed without any problems. According to the pharmaceutical industry on the 8th, the application for voluntary retirement, which was conducted by Novartis Korea for about two weeks, has recently been closed. The company announced the implementation of voluntary retirement on the 25th of last month. Novartis Korea is in the process of integrating and dividing its business units at the same time. The plan is to combine the Rx division and the anti-cancer drug division to unite innovative drugs into one and form a new division that collects patented drugs. New drugs such as Kymriah and Zolgensma are bound to be innovative drugs, and old drugs such as relatively low-cost chronic disease drugs are expected to be classified as patent expired drugs. ERP was also carried out in the process of integrating and dividing business units. The compensation condition is '2n+8' and additional compensation is given for each year. This means that an average salary of eight months is paid twice the number of years of service, and an additional six months' worth of employees for 10 to 15 years of service and 12 months' worth of employees for more than 15 years. It is reported that voluntary retirement is taking place in a relatively quiet atmosphere. It went through a meeting with the labor union before the announcement of his voluntary retirement, and it was found that it was not a coercive atmosphere because it did not specify the target. However, the key is how the company will respond if the applicant falls short of the desired retirement size the company thinks. The higher the number of years of service, the higher the desired retirement compensation. Last year, there was also a backlash against proceeding with voluntary retirement despite no management difficulties due to high profits. The NPU, which includes Novartis Korea, said at a meeting of National Assembly aides on the 7th, "Novartis is the world's most profitable pharmaceutical company last year, and this restructuring is also due to the unification of its business unit, not management reasons." The NPU said, "Novatis Korea also announced its voluntary retirement with a very passive attitude that it has no management difficulties, but has no choice but to follow global decisions." In the process, there is a concern about the risk of forced voluntary retirement, such as encouraging retirement, the NPU said. The union said, "There were some applicants for voluntary retirement, and the exact number of people is being determined. However, it remains to be seen how much the company thinks of voluntary retirement and whether it will make artificial adjustments beyond the legal part if they do not reach that level, he said. In response, the union said, "We have completed the application for voluntary retirement smoothly, and all procedures are conducted transparently and fairly in accordance with the law. The union said, "We will respect the will of our employees as much as possible and will not exercise compulsory pressure such as urging them to retire."
- Policy
- GOV·Pharma starts work to localize 57 essential medicines
- by Lee, Jeong-Hwan Sep 13, 2022 05:52am
- The government and the pharmaceutical industry have entered the final stages of localizing the finished drug products and active pharmaceutical ingredients that are essential for national disease control and prevention as well as the treatment of emergency patients. The supply of such products and ingredients has been mainly dependent on imports despite the evident need to be manufactured and produced in Korea due to low profitability. Among drugs that are imported from 3 or fewer countries and therefore are vulnerable supply-wise, those from highly export-dependent countries of China, Japan, and India will be finally confirmed, upon which the government and the pharmaceutical industry plan to cooperate in securing domestic production technologies. The movement bears significance as it is the first time the government and the pharmaceutical industry joined forces to fundamentally increase the self-sufficiency rate of rare or essential drugs that are subject to stable supply measures in Korea. On the 12th, the Korea Orphan & Essential Drug Center (KODC) announced that it has tentatively finalized the list of 21 finished drugs and 35 APIs that are deemed to be in need of domestic technology development after discussion with the Ministry of Food and Drug Safety (MFDS) and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), and will be collecting opinions from the industry as its last step. After collecting and reviewing opinions submitted by pharmaceutical companies, the KODC will hold an expert advisory meeting and finalize the list. Indications for the 21 tentatively confirmed finished drugs that were chosen due to the diseases’ difficulty in treatment or rarity of their patient group were treatments for emergency hypertension, ulcerative colitis, multiple myeloma, phosphorus excretion, acute heart failure or bradycardia, iron deficiency in patients unable to take oral medications, parasitic infection, adrenogenital syndrome, malignant hyperthermia, iron intoxication, methanol intoxication, Dravet syndrome, etc. Subject products were: Nitroprusside injection, mesalamine suppository·powder, melphalan tablet, bromocriptine oral tablet, sevelamer powder, etomidate injection, amiodarone injection, imiquimod cream, isoproterenol injection, ferric carboxymaltose hydroxide Injections, clarithromycin injections, pentamidine injections, fludrocortisone tablets, nisoldipine tablets, amiodarone hydrochloride tablets, dantrolene sodium injections, deferoxamine injections, dehydrated ethanol injections, stiripentol capsules, anakinra injections, etc. The 36 active pharmaceutical ingredients that were imported from countries with high import-dependency such as China, India, and Japan, are used for Brucellosis tularemia plague, Wilms' tumor, anthrax·plague·tularemia, drug-induced dystonia, Parkinson's disease, acute and chronic diarrhea, hypothyroidism, invasive fungal infection, supraventricular tachycardia, sepsis, tuberculosis, patent ductus arteriosus in preterm infants, Cushing's syndrome, atrophic vaginitis kraurosis vulvae, etc., that pose a fatal threat due to terrorism risk or in disease control and prevention in the nation, or have a rare patient group. The subject ingredients are Levodopa/benserazide tablet, loperamide capsule, liothyronine tablet, lincomycin hydrochloride capsule, voriconazole injection, bisoprolol tablet, salbutamol inhalent, adenosine injection, amiodarone tablet, amikacin injection, Amphotericin B injection, edaravone injection, ethambutol tablet, captopril tablet, clindamycin injection·capsule, pyridoxine injection, albendazole tablet, ketoconazole tablet, etc. The KODC plans to finalize the selection of drugs in need of stable supply after holding an expert advisory meeting on their selection criteria and considering their individual need for development, etc. In addition, in consideration of the potential for domestic development, industry interest, and the international supply network status of drugs that are not on the candidate list, the KODC will be collecting opinions on finished drugs and APIS that the industry believes are in need of domestic manufacturing technologies. A KODC official said, “We ask pharmaceutical companies that have separate opinions on our drug list selection, such as addition or deletion of items or the need for priority development, to submit their reviewed opinions and reasons. We will also be identifying pharmaceutical companies that are willing to produce products that are not yet approved for the manufacture of finished pharmaceuticals on paper, such as APIs in the Drug Master File system that are only being imported in Korea.”. Meanwhile, KODC is in charge of the MFDS’s research project on establishing a stable supply system for products with concerns over unstable supply and demand, focusing on National essential medicines that are used in public health crises.
- Company
- Hanmi’s Rolontis receives US FDA marketing approval
- by Kim, Jin-Gu Sep 13, 2022 05:52am
- Hanmi Pharmaceutical’s neutropenia treatment ‘Rolontis (US product name: Rolvedon)' received approval from the US FDA. Hanmi Pharmaceutical and its partner Spectrum Pharmaceuticals announced on the 9th (local time) that it had received written notice of approval allowing for the marketing authorization of Rolontis from the FDA. This is the first new drug developed by Hanmi Pharmaceutical to be granted marketing authorization by the FDA. In terms of achievements made by the domestic biopharmaceutical industry, Hanmi Pharmaceutical’s approval this time marks the 6th new homegrown drug MA granted by the FDA and is the first among new anticancer drugs Hanmi Pharmaceutical and Spectrum Pharmaceuticals explained that they are ready to launch Rolontis in the US market. The companies expect to have the product available within the year based on the nationwide sales and marketing network they have established in the US. Se-Chang Kwon, President & CEO of Hanmi Pharmaceutical, said, “The approval holds significance as it is Hanmi’s first new drug to be granted approval and the first demonstration of the potential held by the company’s proprietary platform technology, LAPSCOVERY, The approval will be a decisive opportunity for the commercial success of Rolontis and the rise in the future value of new biologics based on LAPSCOVERY.
- Opinion
- [Reporter's view] PVA market should be actively reflected
- by Lee, Tak-Sun Sep 13, 2022 05:51am
- The pharmaceutical industry is in accordance with PVA didn't like being drug price cut. Excessive government intervention in the law according to the principle of supply and demand markets. Other goods has increased the use of demand than supply shortages, needs to be raised prices. But people pay health insurance run to fund health insurance system for the integrity of the principles that are not in arms. The COVID cold medicines such as drug case is a typical example of the increased trend in use. In an emergency due to infectious disease, without reflecting the system would drugs is lowered to in the pharmaceutical industry is concerned. But, but not the government through the correction amount of disadvantage companies contained in the target group cut drug price just worried. Sudden reflex to stop sales profit is a drug containing impurities need medication to take a closer look at the situation. The drugs increased by the use of existing drugs often cheaper than the sales suspension is true, but rather believed to have to reduce the drug price. Whenever these situations unfold, the pharmaceutical industry suggests the Ministry of Health and Welfare or the NHIS to exclude PVA. Each time, the government fully collects opinions from the pharmaceutical industry, but does not reflect all of the industry's claims by citing the purpose or principles of PVA. Some vendors in the end product price to appeal the cut is an injustice to happen happens. The NHIS is currently conducting research services for PVA improvement plans. That are currently fixed up to 10% will raise new standards will increase direct deposits. Most of them are intended to seek expansion and operation of the system for fiscal reduction. But the system of acceptability of the participants to build a broader view of the principles and detailed criteria with the situation and the environment should be reflected in the same time is also necessary. As such, detailed proposals such as national emergency situations caused by infectious diseases and increased use of drugs with reduced finances compared to alternative drugs should not be made to prevent unfair cases. If the system is operated as it is now, consumers will discuss the effectiveness of drug reduction, and on the contrary, suppliers will only highlight unreasonable aspects. We hope that PVA will come up with a more elaborately designed improvement plan.
